Myriad Genetics, Inc.
NASDAQ:MYGN
17.67 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Myriad Genetics, Inc. |
Symbool | MYGN |
Munteenheid | USD |
Prijs | 17.67 |
Beurswaarde | 1,604,796,468 |
Dividendpercentage | 0% |
52-weken bereik | 16 - 29.3 |
Industrie | Diagnostics & Research |
Sector | Healthcare |
CEO | Mr. Paul J. Diaz |
Website | https://myriad.com |
An error occurred while fetching data.
Over Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)